<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04499638</url>
  </required_header>
  <id_info>
    <org_study_id>PR(AG)74/2020</org_study_id>
    <nct_id>NCT04499638</nct_id>
  </id_info>
  <brief_title>Incidence of Complications of Peripheral Venous Access in the Type 2 Diabetic Population</brief_title>
  <official_title>Incidence of Complications of Peripheral Venous Access in the Type 2 Diabetic Population. Analysis of Risk Factors and Comparative Study of Two Peripheral Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes Mellitus type 2 (T2DM) is one of the most frequent metabolic diseases worldwide. It&#xD;
      is expected that in 2035 around 600 million people will suffer from the disease. A recent&#xD;
      systematic review has estimated that the direct annual cost of Diabetes worldwide treatments&#xD;
      and care is over $ 827 billion and has been independently associated with nosocomial&#xD;
      complications, thrombosis-like infections and prolonged admissions. In addition, it is&#xD;
      estimated that up to 90% of patients in acute hospitals require a peripheral venous catheter&#xD;
      which are associated at the same time with mechanical, infectious and thrombotic acute&#xD;
      complications. Recently the emergence of new medium-sized peripheral devices (Midline®) and&#xD;
      new peripheral central venous access catheters (PICC), which are more biocompatible, are&#xD;
      opening new clinical possibilities with the aim of improving safety and comfort during&#xD;
      treatment time and the reduction of associated complications.&#xD;
&#xD;
      With all this, a observational case-control study has been proposed in order to analyze the&#xD;
      impact of T2DM disease and its associated complications on the patient requiring peripheral&#xD;
      venous access. Furthermore investigators will consider if these new peripheral devices can be&#xD;
      a remarkable benefit for these patients. This study will be carried out at the Vall d'Hebron&#xD;
      University Hospital in Barcelona, Spain&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Prospective case-control study will be carry out with patients that will be admitted in&#xD;
      the hospitalization areas of the Vall d'Hebron Hospital. All research data will be collected&#xD;
      by the hospital's vascular access nursing team. Complications related to peripheral venous&#xD;
      access (phlebitis, thrombosis, pain, erythema, extravasation) and the time of catheter&#xD;
      replacement are the focus outcomes of the present study and possible differences between the&#xD;
      control group and the sample population of the T2DM will be analyzed. General clinical and&#xD;
      anthropometric data (age, sex, BMI, toxic habits,...), cause of admission, co-morbidities,&#xD;
      and all variables related to diabetes (time of evolution, degree of glycemic control,&#xD;
      treatment, and presence of chronic complications) will also be collected. If there are any&#xD;
      significant differences, they will be related to the different risk factors associated with&#xD;
      T2DM through association of different epidemiological variables. Furthermore in this&#xD;
      hypothetical case, the research team would intend to develop and carry out molecular studies&#xD;
      through analysis of blood and urine components, proteinomics and genetic studies.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
        -  T2DM is an independent risk factor for catheter-related complications.&#xD;
&#xD;
        -  The use of new vascular access devices (Midline, PICC) in patients with T2DM would be&#xD;
           associated with a lower risk of catheter-related complications.&#xD;
&#xD;
      Main objective:&#xD;
&#xD;
      - To assess the influence of T2DM on complications related to peripheral vascular catheters&#xD;
      in hospitalized patients.&#xD;
&#xD;
      It is expected to colect information of N=500 samples, 250 control group (noT2DM subjects)&#xD;
      and 250 study group (T2DM subjects). Due to previous experience, the sample proposed is&#xD;
      totally acceptable&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">May 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>How is the influence of T2DM on complications related to peripheral vascular catheters in hospitalized patients</measure>
    <time_frame>12 month</time_frame>
    <description>Rate of complications associated with catheters: thrombosis, infection, pain and skin reaction</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Catheterization, Peripheral</condition>
  <condition>Upper Extremity Deep Vein Thrombosis</condition>
  <condition>Catheter-Related Infections</condition>
  <condition>Diabetes Complications</condition>
  <arm_group>
    <arm_group_label>Non type 2 diabetic patient</arm_group_label>
    <description>Tracking the catheter from insertion to removal. Collection of any patients complication associated with these devices and what different treatments has been administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic type 2 patient</arm_group_label>
    <description>Tracking the catheter from insertion to removal.Collection of any patients complication associated with these devices and what different treatments has been administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Peripheral vascular catheters</intervention_name>
    <description>Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal</description>
    <arm_group_label>Diabetic type 2 patient</arm_group_label>
    <arm_group_label>Non type 2 diabetic patient</arm_group_label>
    <other_name>Short canula, Midline, PICC</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to our hospital who require intravenous treatment and a peripheral venous&#xD;
        device has been placed&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Peripheral venous access requirement &gt;7 days&#xD;
&#xD;
          -  Administration of intravenous treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Peripheral venous access for urgent or life-threatening pathology&#xD;
&#xD;
          -  Acute psychiatric pathology&#xD;
&#xD;
          -  Impossibility of peripheral venous access through the upper limb (amputations,&#xD;
             extensive burns, etc.)&#xD;
&#xD;
          -  History of venous thrombosis due to catheter less than 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Simó, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Vall Hebron Research Institute-VHIR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Rivas, Nurse</last_name>
    <phone>676083855</phone>
    <email>marc.rivas@vhir.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Ciudin, Prof.</last_name>
    <phone>697817352</phone>
    <email>aciudin@vhebron.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vall d'Hebron Research Institute-VHIR</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marc Rivas, Nurse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Nowotny K, Jung T, Hohn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015 Mar 16;5(1):194-222. doi: 10.3390/biom5010194.</citation>
    <PMID>25786107</PMID>
  </reference>
  <reference>
    <citation>Asmat U, Abad K, Ismail K. Diabetes mellitus and oxidative stress-A concise review. Saudi Pharm J. 2016 Sep;24(5):547-553. doi: 10.1016/j.jsps.2015.03.013. Epub 2015 Mar 21.</citation>
    <PMID>27752226</PMID>
  </reference>
  <reference>
    <citation>Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50. doi: 10.1056/NEJM200105033441801.</citation>
    <PMID>11333990</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. Standards of Medical Care in Diabetes-2017 Abridged for Primary Care Providers. Clin Diabetes. 2017 Jan;35(1):5-26. doi: 10.2337/cd16-0067. No abstract available.</citation>
    <PMID>28144042</PMID>
  </reference>
  <reference>
    <citation>Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015 Apr 15;6(3):456-80. doi: 10.4239/wjd.v6.i3.456.</citation>
    <PMID>25897356</PMID>
  </reference>
  <reference>
    <citation>Hurrle S, Hsu WH. The etiology of oxidative stress in insulin resistance. Biomed J. 2017 Oct;40(5):257-262. doi: 10.1016/j.bj.2017.06.007. Epub 2017 Nov 8.</citation>
    <PMID>29179880</PMID>
  </reference>
  <reference>
    <citation>Banerjee M, Vats P. Reactive metabolites and antioxidant gene polymorphisms in Type 2 diabetes mellitus. Redox Biol. 2014;2:170-7. doi: 10.1016/j.redox.2013.12.001. Epub 2013 Dec 11.</citation>
    <PMID>25460725</PMID>
  </reference>
  <reference>
    <citation>Ley SH, Ardisson Korat AV, Sun Q, Tobias DK, Zhang C, Qi L, Willett WC, Manson JE, Hu FB. Contribution of the Nurses' Health Studies to Uncovering Risk Factors for Type 2 Diabetes: Diet, Lifestyle, Biomarkers, and Genetics. Am J Public Health. 2016 Sep;106(9):1624-30. doi: 10.2105/AJPH.2016.303314. Epub 2016 Jul 26.</citation>
    <PMID>27459454</PMID>
  </reference>
  <reference>
    <citation>Martin-Timon I, Sevillano-Collantes C, Segura-Galindo A, Del Canizo-Gomez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014 Aug 15;5(4):444-70. doi: 10.4239/wjd.v5.i4.444.</citation>
    <PMID>25126392</PMID>
  </reference>
  <reference>
    <citation>Lowe G, Woodward M, Hillis G, Rumley A, Li Q, Harrap S, Marre M, Hamet P, Patel A, Poulter N, Chalmers J. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014 Mar;63(3):1115-23. doi: 10.2337/db12-1625. Epub 2013 Nov 12.</citation>
    <PMID>24222348</PMID>
  </reference>
  <reference>
    <citation>Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015 Aug;33(8):811-31. doi: 10.1007/s40273-015-0268-9.</citation>
    <PMID>25787932</PMID>
  </reference>
  <reference>
    <citation>Sayampanathan AA. Systematic review of complications and outcomes of diabetic patients with burn trauma. Burns. 2016 Dec;42(8):1644-1651. doi: 10.1016/j.burns.2016.06.023. Epub 2016 Aug 29.</citation>
    <PMID>27595452</PMID>
  </reference>
  <reference>
    <citation>Low ZK, Ng WY, Fook-Chong S, Tan BK, Chong SJ, Hwee J, Tay SM. Comparison of clinical outcomes in diabetic and non-diabetic burns patients in a national burns referral center in Southeast Asia: A 3-year retrospective review; Methodological issues. Burns. 2017 Sep;43(6):1368. doi: 10.1016/j.burns.2017.03.019. Epub 2017 Jun 9. No abstract available.</citation>
    <PMID>28602590</PMID>
  </reference>
  <reference>
    <citation>Vondran M, Schack S, Garbade J, Binner C, Mende M, Rastan AJ, Borger MA, Schroeter T. Evaluation of risk factors for a fulminant Clostridium difficile infection after cardiac surgery: a single-center, retrospective cohort study. BMC Anesthesiol. 2018 Sep 27;18(1):133. doi: 10.1186/s12871-018-0597-2.</citation>
    <PMID>30257648</PMID>
  </reference>
  <reference>
    <citation>Keogh S, Marsh N, Higgins N, Davies K, Rickard C. A time and motion study of peripheral venous catheter flushing practice using manually prepared and prefilled flush syringes. J Infus Nurs. 2014 Mar-Apr;37(2):96-101. doi: 10.1097/NAN.0000000000000024.</citation>
    <PMID>24583939</PMID>
  </reference>
  <reference>
    <citation>Bomberg H, Kubulus C, List F, Albert N, Schmitt K, Graber S, Kessler P, Steinfeldt T, Standl T, Gottschalk A, Wirtz SP, Burgard G, Geiger P, Spies CD, Volk T; German Network for Regional Anaesthesia Investigators. Diabetes: a risk factor for catheter-associated infections. Reg Anesth Pain Med. 2015 Jan-Feb;40(1):16-21. doi: 10.1097/AAP.0000000000000196.</citation>
    <PMID>25474624</PMID>
  </reference>
  <reference>
    <citation>Liem TK, Yanit KE, Moseley SE, Landry GJ, Deloughery TG, Rumwell CA, Mitchell EL, Moneta GL. Peripherally inserted central catheter usage patterns and associated symptomatic upper extremity venous thrombosis. J Vasc Surg. 2012 Mar;55(3):761-7. doi: 10.1016/j.jvs.2011.10.005.</citation>
    <PMID>22370026</PMID>
  </reference>
  <reference>
    <citation>Bahl A, Hang B, Brackney A, Joseph S, Karabon P, Mohammad A, Nnanabu I, Shotkin P. Standard long IV catheters versus extended dwell catheters: A randomized comparison of ultrasound-guided catheter survival. Am J Emerg Med. 2019 Apr;37(4):715-721. doi: 10.1016/j.ajem.2018.07.031. Epub 2018 Jul 19.</citation>
    <PMID>30037560</PMID>
  </reference>
  <reference>
    <citation>Pittiruti M, Brutti A, Celentano D, Pomponi M, Biasucci DG, Annetta MG, Scoppettuolo G. Clinical experience with power-injectable PICCs in intensive care patients. Crit Care. 2012 Feb 4;16(1):R21. doi: 10.1186/cc11181.</citation>
    <PMID>22305301</PMID>
  </reference>
  <reference>
    <citation>Potet J, Arnaud FX, Thome A, Weber-Donat G, Konopacki J, Bouzad C, Kervella Y, Erauso T, Garcia G, Evelyne P, Valbousquet L, Baccialone J, Teriitehau CA. Peripherally inserted central catheter placement in patients with coagulation disorders: A retrospective analysis. Diagn Interv Imaging. 2015 Nov;96(11):1147-51. doi: 10.1016/j.diii.2014.12.012. Epub 2015 May 27.</citation>
    <PMID>26025158</PMID>
  </reference>
  <reference>
    <citation>Gao Y, Fan X, Han J. Prognostic factors for venous thrombosis in patients with peripherally inserted central catheters: Protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2020 Jul 10;99(28):e21037. doi: 10.1097/MD.0000000000021037.</citation>
    <PMID>32664112</PMID>
  </reference>
  <reference>
    <citation>Miliani K, Taravella R, Thillard D, Chauvin V, Martin E, Edouard S, Astagneau P; CATHEVAL Study Group. Peripheral Venous Catheter-Related Adverse Events: Evaluation from a Multicentre Epidemiological Study in France (the CATHEVAL Project). PLoS One. 2017 Jan 3;12(1):e0168637. doi: 10.1371/journal.pone.0168637. eCollection 2017.</citation>
    <PMID>28045921</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>July 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus Type 2</keyword>
  <keyword>Catheter-Related complications</keyword>
  <keyword>Short peripheral venous catheter</keyword>
  <keyword>Medium line peripheral catheter (Midline)</keyword>
  <keyword>Peripheral Insertion Central Catheter (PICC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Catheter-Related Infections</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Upper Extremity Deep Vein Thrombosis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04499638
org study id: PR(AG)74/2020
nct id: NCT04499638
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Diabetes Mellitus type 2 (T2DM) is one of the most frequent metabolic diseases worldwide. It
      is expected that in 2035 around 600 million people will suffer from the disease. A recent
      systematic review has estimated that the direct annual cost of Diabetes worldwide treatments
      and care is over $ 827 billion and has been independently associated with nosocomial
      complications, thrombosis-like infections and prolonged admissions. In addition, it is
      estimated that up to 90% of patients in acute hospitals require a peripheral venous catheter
      which are associated at the same time with mechanical, infectious and thrombotic acute
      complications. Recently the emergence of new medium-sized peripheral devices (Midline®) and
      new peripheral central venous access catheters (PICC), which are more biocompatible, are
      opening new clinical possibilities with the aim of improving safety and comfort during
      treatment time and the reduction of associated complications.

      With all this, a observational case-control study has been proposed in order to analyze the
      impact of T2DM disease and its associated complications on the patient requiring peripheral
      venous access. Furthermore investigators will consider if these new peripheral devices can be
      a remarkable benefit for these patients. This study will be carried out at the Vall d'Hebron
      University Hospital in Barcelona, Spain
This Prospective case-control study will be carry out with patients that will be admitted in
      the hospitalization areas of the Vall d'Hebron Hospital. All research data will be collected
      by the hospital's vascular access nursing team. Complications related to peripheral venous
      access (phlebitis, thrombosis, pain, erythema, extravasation) and the time of catheter
      replacement are the focus outcomes of the present study and possible differences between the
      control group and the sample population of the T2DM will be analyzed. General clinical and
      anthropometric data (age, sex, BMI, toxic habits,...), cause of admission, co-morbidities,
      and all variables related to diabetes (time of evolution, degree of glycemic control,
      treatment, and presence of chronic complications) will also be collected. If there are any
      significant differences, they will be related to the different risk factors associated with
      T2DM through association of different epidemiological variables. Furthermore in this
      hypothetical case, the research team would intend to develop and carry out molecular studies
      through analysis of blood and urine components, proteinomics and genetic studies.

      Hypothesis:

        -  T2DM is an independent risk factor for catheter-related complications.

        -  The use of new vascular access devices (Midline, PICC) in patients with T2DM would be
           associated with a lower risk of catheter-related complications.

      Main objective:

      - To assess the influence of T2DM on complications related to peripheral vascular catheters
      in hospitalized patients.

      It is expected to colect information of N=500 samples, 250 control group (noT2DM subjects)
      and 250 study group (T2DM subjects). Due to previous experience, the sample proposed is
      totally acceptable
observational model: Case-Control
time perspective: Prospective
measure: How is the influence of T2DM on complications related to peripheral vascular catheters in hospitalized patients
time frame: 12 month
description: Rate of complications associated with catheters: thrombosis, infection, pain and skin reaction
arm group label: Non type 2 diabetic patient
description: Tracking the catheter from insertion to removal. Collection of any patients complication associated with these devices and what different treatments has been administered
arm group label: Diabetic type 2 patient
description: Tracking the catheter from insertion to removal.Collection of any patients complication associated with these devices and what different treatments has been administered
intervention type: Device
intervention name: Peripheral vascular catheters
description: Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal
arm group label: Diabetic type 2 patient
arm group label: Non type 2 diabetic patient
other name: Short canula, Midline, PICC
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 40 Years
maximum age: 90 Years
healthy volunteers: No
last name: Rafael Simó, Prof.
role: Study Director
affiliation: Vall Hebron Research Institute-VHIR
last name: Marc Rivas, Nurse
phone: 676083855
email: marc.rivas@vhir.org
last name: Andrea Ciudin, Prof.
phone: 697817352
email: aciudin@vhebron.net
facility: 
status: Recruiting
investigator: 
country: Spain
citation: Nowotny K, Jung T, Hohn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015 Mar 16;5(1):194-222. doi: 10.3390/biom5010194.
PMID: 25786107
citation: Asmat U, Abad K, Ismail K. Diabetes mellitus and oxidative stress-A concise review. Saudi Pharm J. 2016 Sep;24(5):547-553. doi: 10.1016/j.jsps.2015.03.013. Epub 2015 Mar 21.
PMID: 27752226
citation: Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50. doi: 10.1056/NEJM200105033441801.
PMID: 11333990
citation: American Diabetes Association. Standards of Medical Care in Diabetes-2017 Abridged for Primary Care Providers. Clin Diabetes. 2017 Jan;35(1):5-26. doi: 10.2337/cd16-0067. No abstract available.
PMID: 28144042
citation: Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015 Apr 15;6(3):456-80. doi: 10.4239/wjd.v6.i3.456.
PMID: 25897356
citation: Hurrle S, Hsu WH. The etiology of oxidative stress in insulin resistance. Biomed J. 2017 Oct;40(5):257-262. doi: 10.1016/j.bj.2017.06.007. Epub 2017 Nov 8.
PMID: 29179880
citation: Banerjee M, Vats P. Reactive metabolites and antioxidant gene polymorphisms in Type 2 diabetes mellitus. Redox Biol. 2014;2:170-7. doi: 10.1016/j.redox.2013.12.001. Epub 2013 Dec 11.
PMID: 25460725
citation: Ley SH, Ardisson Korat AV, Sun Q, Tobias DK, Zhang C, Qi L, Willett WC, Manson JE, Hu FB. Contribution of the Nurses' Health Studies to Uncovering Risk Factors for Type 2 Diabetes: Diet, Lifestyle, Biomarkers, and Genetics. Am J Public Health. 2016 Sep;106(9):1624-30. doi: 10.2105/AJPH.2016.303314. Epub 2016 Jul 26.
PMID: 27459454
citation: Martin-Timon I, Sevillano-Collantes C, Segura-Galindo A, Del Canizo-Gomez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014 Aug 15;5(4):444-70. doi: 10.4239/wjd.v5.i4.444.
PMID: 25126392
citation: Lowe G, Woodward M, Hillis G, Rumley A, Li Q, Harrap S, Marre M, Hamet P, Patel A, Poulter N, Chalmers J. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014 Mar;63(3):1115-23. doi: 10.2337/db12-1625. Epub 2013 Nov 12.
PMID: 24222348
citation: Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015 Aug;33(8):811-31. doi: 10.1007/s40273-015-0268-9.
PMID: 25787932
citation: Sayampanathan AA. Systematic review of complications and outcomes of diabetic patients with burn trauma. Burns. 2016 Dec;42(8):1644-1651. doi: 10.1016/j.burns.2016.06.023. Epub 2016 Aug 29.
PMID: 27595452
citation: Low ZK, Ng WY, Fook-Chong S, Tan BK, Chong SJ, Hwee J, Tay SM. Comparison of clinical outcomes in diabetic and non-diabetic burns patients in a national burns referral center in Southeast Asia: A 3-year retrospective review; Methodological issues. Burns. 2017 Sep;43(6):1368. doi: 10.1016/j.burns.2017.03.019. Epub 2017 Jun 9. No abstract available.
PMID: 28602590
citation: Vondran M, Schack S, Garbade J, Binner C, Mende M, Rastan AJ, Borger MA, Schroeter T. Evaluation of risk factors for a fulminant Clostridium difficile infection after cardiac surgery: a single-center, retrospective cohort study. BMC Anesthesiol. 2018 Sep 27;18(1):133. doi: 10.1186/s12871-018-0597-2.
PMID: 30257648
citation: Keogh S, Marsh N, Higgins N, Davies K, Rickard C. A time and motion study of peripheral venous catheter flushing practice using manually prepared and prefilled flush syringes. J Infus Nurs. 2014 Mar-Apr;37(2):96-101. doi: 10.1097/NAN.0000000000000024.
PMID: 24583939
citation: Bomberg H, Kubulus C, List F, Albert N, Schmitt K, Graber S, Kessler P, Steinfeldt T, Standl T, Gottschalk A, Wirtz SP, Burgard G, Geiger P, Spies CD, Volk T; German Network for Regional Anaesthesia Investigators. Diabetes: a risk factor for catheter-associated infections. Reg Anesth Pain Med. 2015 Jan-Feb;40(1):16-21. doi: 10.1097/AAP.0000000000000196.
PMID: 25474624
citation: Liem TK, Yanit KE, Moseley SE, Landry GJ, Deloughery TG, Rumwell CA, Mitchell EL, Moneta GL. Peripherally inserted central catheter usage patterns and associated symptomatic upper extremity venous thrombosis. J Vasc Surg. 2012 Mar;55(3):761-7. doi: 10.1016/j.jvs.2011.10.005.
PMID: 22370026
citation: Bahl A, Hang B, Brackney A, Joseph S, Karabon P, Mohammad A, Nnanabu I, Shotkin P. Standard long IV catheters versus extended dwell catheters: A randomized comparison of ultrasound-guided catheter survival. Am J Emerg Med. 2019 Apr;37(4):715-721. doi: 10.1016/j.ajem.2018.07.031. Epub 2018 Jul 19.
PMID: 30037560
citation: Pittiruti M, Brutti A, Celentano D, Pomponi M, Biasucci DG, Annetta MG, Scoppettuolo G. Clinical experience with power-injectable PICCs in intensive care patients. Crit Care. 2012 Feb 4;16(1):R21. doi: 10.1186/cc11181.
PMID: 22305301
citation: Potet J, Arnaud FX, Thome A, Weber-Donat G, Konopacki J, Bouzad C, Kervella Y, Erauso T, Garcia G, Evelyne P, Valbousquet L, Baccialone J, Teriitehau CA. Peripherally inserted central catheter placement in patients with coagulation disorders: A retrospective analysis. Diagn Interv Imaging. 2015 Nov;96(11):1147-51. doi: 10.1016/j.diii.2014.12.012. Epub 2015 May 27.
PMID: 26025158
citation: Gao Y, Fan X, Han J. Prognostic factors for venous thrombosis in patients with peripherally inserted central catheters: Protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2020 Jul 10;99(28):e21037. doi: 10.1097/MD.0000000000021037.
PMID: 32664112
citation: Miliani K, Taravella R, Thillard D, Chauvin V, Martin E, Edouard S, Astagneau P; CATHEVAL Study Group. Peripheral Venous Catheter-Related Adverse Events: Evaluation from a Multicentre Epidemiological Study in France (the CATHEVAL Project). PLoS One. 2017 Jan 3;12(1):e0168637. doi: 10.1371/journal.pone.0168637. eCollection 2017.
PMID: 28045921
responsible party type: Sponsor
mesh term: Catheter-Related Infections
mesh term: Thrombosis
mesh term: Venous Thrombosis
mesh term: Upper Extremity Deep Vein Thrombosis
mesh term: Diabetes Mellitus
mesh term: Diabetes Mellitus, Type 2
mesh term: Diabetes Complications